Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.

Nyombayire J, Anzala O, Gazzard B, Karita E, Bergin P, Hayes P, Kopycinski J, Omosa-Manyonyi G, Jackson A, Bizimana J, Farah B, Sayeed E, Parks CL, Inoue M, Hironaka T, Hara H, Shu T, Matano T, Dally L, Barin B, Park H, Gilmour J, Lombardo A, Excler JL, Fast P, Laufer DS, Cox JH; S001 Study Team.

J Infect Dis. 2017 Jan 1;215(1):95-104. doi: 10.1093/infdis/jiw500. Epub 2016 Oct 17.

2.

Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.

Baden LR, Karita E, Mutua G, Bekker LG, Gray G, Page-Shipp L, Walsh SR, Nyombayire J, Anzala O, Roux S, Laher F, Innes C, Seaman MS, Cohen YZ, Peter L, Frahm N, McElrath MJ, Hayes P, Swann E, Grunenberg N, Grazia-Pau M, Weijtens M, Sadoff J, Dally L, Lombardo A, Gilmour J, Cox J, Dolin R, Fast P, Barouch DH, Laufer DS; B003-IPCAVD004-HVTN091 Study Group.

Ann Intern Med. 2016 Mar 1;164(5):313-22. doi: 10.7326/M15-0880. Epub 2016 Feb 2.

3.

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC.

J Virol. 2009 Jul;83(14):7337-48. doi: 10.1128/JVI.00110-09. Epub 2009 May 13.

4.

Controlling invasive pneumococcal disease: is vaccination of at-risk groups sufficient?

Fletcher MA, Laufer DS, McIntosh ED, Cimino C, Malinoski FJ.

Int J Clin Pract. 2006 Apr;60(4):450-6. Review.

5.

Pneumonia vaccine.

Malinoski FJ, Laufer DS.

J Fam Pract. 2001 Oct;50(10):902. No abstract available.

PMID:
11674899
6.

Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.

Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE.

J Infect Dis. 1996 Mar;173(3):731-4. Erratum in: J Infect Dis 1996 Jun;173(6):1529.

PMID:
8627041
7.

Resistance to antivirals.

Laufer DS, Starr SE.

Pediatr Clin North Am. 1995 Jun;42(3):583-99. Review.

PMID:
7761142
8.

Saliva and serum as diagnostic media for antibody to hepatitis A virus in adults and in individuals who have received an inactivated hepatitis A vaccine.

Laufer DS, Hurni W, Watson B, Miller W, Ryan J, Nalin D, Brown L.

Clin Infect Dis. 1995 Apr;20(4):868-71.

PMID:
7795087

Supplemental Content

Loading ...
Support Center